SLC5A2 and type 2 diabetes mellitus: However, certain drawbacks like cost, injection, and limited availability with GLP-1RAs and increased risk of genital and urinary tract infections, hypovolemia, postural hypotension, and weight loss with SGLT2 inhibitors may limit their usage in some older T2DM patients [10].